U.S. markets closed

Evogene Ltd. (EVGN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.7548-0.0752 (-9.06%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close0.8300
Bid0.7110 x 900
Ask0.7910 x 1100
Day's Range0.7200 - 0.8120
52 Week Range0.6800 - 2.9300
Avg. Volume106,222
Market Cap31.768M
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-0.7190
Earnings DateAug 31, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EVGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Evogene Ltd.
    Daily – Vickers Top Buyers & Sellers for 01/14/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • PR Newswire

    Canonic Launches its Second-Generation Medical Cannabis Products with High THC and Unique Terpene Profiles

    Canonic Ltd., focused on the development of medical grade cannabis products and a wholly owned subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced the launch of its second-generation products in Israel. The design of the new products leverages market feedback since Canonic's launch of its first-generation products in Israel in September 2021. The first new product from the second-generation product-line is expected to debut for patients in early October 2022. The rest of the s

  • PR Newswire

    Lavie Bio Announces Appointment of Guri Oron as CEO

    Lavie Bio Ltd. ("Lavie Bio"), a subsidiary of Evogene Ltd. ("Evogene") (Nasdaq: EVGN), (TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today announced the appointment of Guri Oron as Chief Executive Officer ("CEO") of Lavie Bio, effective as of September 18, 2022.

  • PR Newswire

    Canonic Advances its Penetration into Europe by Signing its First Licensing Agreement with GroVida

    Canonic Ltd., focused on the development of medical grade cannabis products and a wholly owned subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced today that it has signed a non-exclusive licensing agreement with leading Portugal-based cannabis cultivation and manufacturing company, GroVida Lda. Under the agreement, GroVida will cultivate, market and sell products based on Canonic's cannabis varieties in Europe and the United Kingdom, and will pay Canonic royalties on its sales bas